drugset / Trial / NCT07829029
Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH
Phase 4
Recruiting
270 enrolled
University of California, San Francisco
National Institute on Aging (NIA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed tocompare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonistbladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinaryincontinence and either normal or mildly impaired cognitive function at baseline.
Timeline
- Start
- 2022-10-04
- Primary completion
- 2027-05-02
- Completion
- 2027-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | — | — |
| Comparator | Tolterodine | Unknown | — | — |
Indications
No indication recorded.